News
We bring you up to date at all times: Discover the latest industry news from biotechnology, pharmaceuticals and life sciences. Researched by us so you don't have to.
Selected departments
Selected industries
Companies
The Who's Who of Life Sciences: Discover companies from all over the world. Here you can easily find the provider matching your search, including contact options.
Selected countries
Selected companies
Products
The first stop for your procurement process: discover innovative products for lab and process that make your everyday life easier and solve even complex challenges.
Products of selected companies
White papers
What could be better than an application problem that has already been solved by others? Tap into in-depth application knowledge from proven experts. Conveniently via download to your device.
Most read white papers
White papers of selected companies
Webinars
Exciting lectures and practical application tips via video, whenever you want: Our on-demand webinars make it possible. Make yourself comfortable and click play.
Selected webinars
Webinars of selected companies
Knowledge & education
Question. Answer. Find articles on 57,945 keywords in life science, biotech, pharma, biology and related science disciplines in the encyclopedia..
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Note
The function "Store search" is only available to registered users.
Important information
Currently, you are not logged in to my.bionity.com. Therefore, you can remember a maximum of 5 contents.
FILTER
Refine your search with the following facets to narrow down your results.
03-Jan-2007 - Crucell N.V. announced that it has signed a cross-licensing agreement with Merck & Co., Inc. In addition to previously licensed rights to PER.C6, the agreement opens the way for Merck to use Crucell technology on an exclusive basis in additional undisclosed vaccine fields. In return, Crucell ...
27-Oct-2006 - Crucell N.V. announced that it has started the phase I clinical trial of the AdVac®-based tuberculosis vaccine it is developing in partnership with The AERAS Global TB Vaccine Foundation. The clinical trial will be an open-label study that will test the vaccine in a dose-escalation trial ...
20-Oct-2006 - Medicines for Malaria Venture (MMV), Genzyme Corp., and the Broad Institute of MIT and Harvard announced that they have expanded their collaboration to discover and advance new therapeutic candidates for malaria. The alliance will build on work begun earlier this year and will enable the ...
05-Sep-2006 - Plasmodium falciparium is the name of by far the most virulent of the four malaria parasites that infect man. It is particularly dangerous in that it also infects the placenta of pregnant women, with fatal consequences for both her and the foetus. This, combined with the often feeble medical ...
NYU scientists begin second phase of project to better understand disease
29-Jun-2006 - A team of researchers at New York University's Center for Comparative Functional Genomics are embarking on the second phase of a collaborative research undertaking to predict structures of key proteins, which in turn shed light on their roles in diseases and offer pathways for cures. The ...
21-Apr-2006 - CEL-SCI Corporation announced that its CEL-1000 peptide showed adjuvant activity when used with a peptide based malaria vaccine and a DNA based malaria vaccine in animal challenge studies as part of a Cooperative Research arrangement with the Naval Medical Research Center, Silver Spring, MD. In ...
19-Apr-2006 - Researchers striving to create a less expensive version of a life-saving antimalarial drug, artemisinin, have cleared a major hurdle, according to a new report in the journal Nature. Two and a half years ago, a University of California, Berkeley, team led by Jay D. Keasling, UC Berkeley professor ...
12-Apr-2006 - Genzyme Corp. announced that it has established a program to participate in efforts to discover and advance novel treatments for neglected diseases affecting the developing world. The company's new Humanitarian Assistance for Neglected Diseases initiative (HAND) will serve as a vehicle to ...
27-Dec-2005 - Crucell N.V. announced that it has signed a Cooperative Research and Development Agreement (CRADA) with the Walter Reed Army Institute of Research (WRAIR) to evaluate Crucell's PER.C6® technology for the development of vaccines against the flaviviruses dengue fever and Japanese encephalitis ...
The malaria vaccine GMZ2 to be tested in a Phase I clinical trial in Tübingen
23-Dec-2005 - Vakzine Projekt Management GmbH (VPM) and the European Malaria Vaccine Initiative (EMVI) are cooperating in compiling and submitting the Phase I clinical trial application of malaria vaccine GMZ2 to the Paul-Ehrlich-Institute and to the Ethics Committee Tübingen, Germany. In addition, VPM shall ...
© 1997-2024 LUMITOS AG, All rights reserved